特发性炎症性肌病中的I型干扰素生物标志物:Siglec-1与疾病活动度及治疗反应的关系
基于19例新诊断成人特发性炎症性肌病患者和9例健康对照的PBMC样本,采用流式细胞术检测单核细胞Siglec-1表达。所有患者基线Siglec-1升高,皮肌炎患者相对中位荧光强度最高;9周后15例有随访样本中10例Siglec-1下降。在皮肌炎中Siglec-1与MMT、PhGA及TIS相关。
要点
- 所有新诊断成人特发性炎症性肌病患者基线Siglec-1表达均升高。
- 皮肌炎患者Siglec-1相对中位荧光强度最高。
- 静脉注射免疫球蛋白单药治疗9周后,15例有随访样本中10例Siglec-1表达下降。
核心结论
- Siglec-1在未治疗的特发性炎症性肌病患者中升高,静脉注射免疫球蛋白单药治疗后下降。
- 在皮肌炎中,Siglec-1表达与相关临床指标相关。
- 这凸显了I型干扰素在特发性炎症性肌病中的动态作用及Siglec-1的生物标志物潜力,尤其在皮肌炎中。
研究设计与样本
- 分析19例新诊断成人特发性炎症性肌病患者(参与一项静脉注射免疫球蛋白单药治疗疗效的2期先导研究)及9例健康对照的PBMC样本。
- 采用流式细胞术检测治疗前后单核细胞Siglec-1表达,并与特发性炎症性肌病亚型、医生整体活动度评分、手工肌力测试及总改善评分进行关联评估。
主要发现
- 诊断包括皮肌炎9例、免疫介导坏死性肌病5例、非特异性/重叠肌炎4例、抗合成酶综合征1例。
- 所有患者基线Siglec-1表达均升高,皮肌炎患者Siglec-1相对中位荧光强度最高。
- 9周后15例有随访样本,其中10例Siglec-1表达下降。
- 在皮肌炎中,Siglec-1与手工肌力测试相关(rs=-0.603,P=0.013),与医生整体活动度评分相关(rs=0.783,P<0.001),与总改善评分相关(rs=-0.786,P=0.036)。
临床怎么用
- 作者认为这些发现应在更大规模、更长随访的队列中进一步验证。
局限性
- 作者指出这些发现应在更大规模、更长随访的队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Novel biomarkers are needed to guide therapy in idiopathic inflammatory myopathies (IIM). Expression of Siglec-1, a type I interferon biomarker, was examined in adult patients with IIM in relation to disease activity and treatment response. METHODS: We analyzed PBMC samples from 19 newly diagnosed adult IIM patients who participated in a phase-2 pilot study on efficacy of intravenous immunoglobulin (IVIG) monotherapy, and from 9 healthy controls. Siglec-1 expression on monocytes was measured by flow cytometry before and after treatment, and was evaluated in relation to IIM subtype, physician global activity (PhGA) scores, manual muscle strength (MMT) and the total improvement score (TIS). RESULTS: Diagnoses included dermatomyositis (DM; n = 9), immune-mediated necrotizing myopathy (IMNM; n = 5), non-specific/overlap myositis (NSM/OM; n = 4) and antisynthetase syndrome (ASyS; n = 1). All patients showed increased Siglec-1 expression at baseline. Relative median fluorescence intensity of Siglec-1 was highest in patients with DM. After 9 weeks, follow-up samples were available for 15 patients of whom 10 patients showed a decline in Siglec-1 expression. In DM, Siglec-1 correlated with disease activity (MMT; rs = -0.603, P = 0.013 and PhGA; rs = 0.783, P < 0.001) and with the TIS (rs = -0.786, P = 0.036). CONCLUSION: Siglec-1 was increased in treatment-naive IIM patients and showed a decline after IVIG monotherapy. In DM, Siglec-1 expression correlated with relevant clinical measures. This underlines the dynamic role of type I IFN in IIM and the biomarker potential of Siglec-1, in particular in DM. These findings should be further validated in larger cohorts with longer follow-up.
引用
- Kamperman RG, Veldkamp SR, Evers SW, et al. Type I interferon biomarker in idiopathic inflammatory myopathies: associations of Siglec-1 with disease activity and treatment response. Rheumatology (Oxford). 2025. PMID: 39563518. doi:10.1093/rheumatology/keae630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。